Moderna
MRNA
#1004
Rank
NZ$42.49 B
Marketcap
NZ$107.10
Share price
11.55%
Change (1 day)
152.32%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

P/E ratio for Moderna (MRNA)

P/E ratio as of June 2026 (TTM): -7.58

According to Moderna 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.58282. At the end of 2025 the company had a P/E ratio of -4.06.

P/E ratio history for Moderna from 2018 to 2026

PE ratio at the end of each year

Year P/E ratio Change
2025-4.06-9.47%
2024-4.48-44.22%
2023-8.03-194.45%
20228.501.4%
20218.39-115.58%
2020-53.9326.19%
2019-12.6-6.41%
2018-13.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
26.8-453.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
21.5-383.44%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Merck
MRK
32.5-527.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-11.2 47.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-0.0045-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
74.6-1,083.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Arrowhead Pharmaceuticals
ARWR
232-3,153.52%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.